Another larger, randomized, phase III trial demonstrated that recurrence of all-cause cardiovascular events was reduced in patients with prior myocardial infarction receiving IL-1 inhibitors, accompanied by a marked decrease in the level of high-sensitivity C-reactive protein (HR: 0.8, 95%CI 0.73–0.95; P = 0.05) (37). This evidence concerns the gene CRP and myocardial infarction.